Nicotine-induced anxiogenic-like behaviours of rats in the elevated plus-maze: Possible role of NMDA receptors of the central amygdala

Journal of Psychopharmacology

Volumn 26, Issue 4, 2012, Pages 555-563

  Zarrindast, Mohammad Reza ^a,b,c,d   Aghamohammadi Sereshki, Arash ^e   Rezayof, Ameneh ^f   Rostami, Parvin ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c INSTITUTE FOR RESEARCH IN FUNDAMENTAL SCIENCES IPM   (Iran)

^d INSTITUTE FOR COGNITIVE SCIENCE STUDIES   (Iran)

^e KHARAZMI UNIVERSITY   (Iran)

^f UNIVERSITY OF TEHRAN   (Iran)

Author keywords

anxiogenic effect; D AP5; elevated plus maze; Nicotine; NMDA; rat

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ANXIOGENIC LIKE EFFECT; ARTICLE; CANNULA; CENTRAL NUCLEUS (AMYGDALA); DRUG EFFECT; ELEVATED PLUS MAZE; EXPERIMENTAL TEST; GLUTAMATE TRANSMISSION; LOCOMOTION; MALE; MICROINJECTION; NEUROTRANSMISSION; NONHUMAN; OPEN ARM ENTRY; OPEN ARM TIME; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY; WISTAR RAT;

2-AMINO-5-PHOSPHONOVALERATE; AMYGDALA; ANIMALS; ANXIETY; MALE; MAZE LEARNING; N-METHYLASPARTATE; NICOTINE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84860182161     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111412094     Document Type: Article

References (71)

1. Ardjmand A, Rezayof A, Zarrindast MR. Involvement of central amygdala NMDA receptor mechanism in morphine state-dependent memory retrieval. Neurosci Res. 2010 ; 69: 25-31
2. Balfour DJ. The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handb Exp Pharmacol. 2009 ; 192: 209-233
3. Barazangi N, Role LW. Nicotine-induced enhancement of glutamatergic and GABAergic synaptic transmission in the mouse amygdala. J Neurophysiol. 2001 ; 86: 463-474
4. Barkus C, McHugh SB, Sprengel R, Seeburg PH, Rawlins JN, Bannerman DM. Hippocampal NMDA receptors and anxiety: At the interface between cognition and emotion. Eur J Pharmacol. 2010 ; 626: 49-56
5. Bergink V, van Megen HJ, Westenberg HG. Glutamate and anxiety. Eur Neuropsychopharmacol. 2004 ; 14: 175-183
6. Biala G, Budzynska B. Effects of acute and chronic nicotine on elevated plus maze in mice: Involvement of calcium channels. Life Sci. 2006 ; 79: 81-88
7. Biala G, Kruk M. Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice. J Pharm Pharmacol. 2009 ; 61: 493-502
8. Blokhina EA, Kashkin VA, Zvartau EE, Danysz W, Bespalov AY. Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur Neuropsychopharmacol. 2005 ; 15: 219-225
9. Brioni JD, O'Neill AB, Kim DJ, Buckley MJ, Decker MW, Arneric SP. Anxiolytic-like effects of the novel cholinergic channel activator ABT-418. J Pharmacol Exp Ther. 1994 ; 271: 353-361
10. Brioni JD, O'Neill AB, Kim DJ, Decker MW. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol. 1993 ; 238: 1-8
11. Brody AL. Functional brain imaging of tobacco use and dependence. J Psychiatr Res. 2006 ; 40: 404-418
12. Carobrez AP, Teixeira KV, Graeff FG. Modulation of defensive behavior by periaqueductal gray NMDA/glycine-B receptor. Neurosci Biobehav Rev. 2001 ; 25: 697-709
13. Cheeta S, Irvine E, File SE. Social isolation modifies nicotine's effects in animal tests of anxiety. Br J Pharmacol. 2001a ; 132: 1389-1395
14. Cheeta S, Irvine EE, Tucci S, Sandhu J, File SE. In adolescence, female rats are more sensitive to the anxiolytic effect of nicotine than are male rats. Neuropsychopharmacology. 2001b ; 25: 601-607
15. Chojnacka-Wojcik E, Klodzinska A, Pilc A. Glutamate receptor ligands as anxiolytics. Curr Opin Investig Drugs. 2001 ; 2: 1112-1119
16. Ciamei A, Aversano M, Cestari V, Castellano C. Effects of MK-801 and nicotine combinations on memory consolidation in CD1 mice. Psychopharmacology (Berl). 2001 ; 154: 126-130
17. Cortese BM, Phan KL. The role of glutamate in anxiety and related disorders. CNS Spectr. 2005 ; 10: 820-830
18. Davidson RJ. Anxiety and affective style: Role of prefrontal cortex and amygdala. Biol Psychiatry. 2002 ; 51: 68-80
19. Davis M. Neural systems involved in fear and anxiety measured with fear-potentiated startle. Am Psychol. 2006 ; 61: 741-756
20. Fallon S, Shearman E, Sershen H, Lajtha A. The effects of glutamate and GABA receptor antagonists on nicotine-induced neurotransmitter changes in cognitive areas. Neurochem Res. 2007 ; 32: 535-553
21. File SE, Kenny PJ, Ouagazzal AM. Bimodal modulation by nicotine of anxiety in the social interaction test: Role of the dorsal hippocampus. Behav Neurosci. 1998 ; 112: 1423-1429
22. Fu Y, Matta SG, Gao W, Brower VG, Sharp BM. Systemic nicotine stimulates dopamine release in nucleus accumbens: Re-evaluation of the role of N-methyl-d-aspartate receptors in the ventral tegmental area. J Pharmacol Exp Ther. 2000 ; 294: 458-465
23. Gao M, Jin Y, Yang K, Zhang D, Lukas RJ, Wu J. Mechanisms involved in systemic nicotine-induced glutamatergic synaptic plasticity on dopamine neurons in the ventral tegmental area. J Neurosci. 2010 ; 30: 13,814-13,825
24. Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med. 2006 ; 73: 941-949
25. Glick SD, Maisonneuve IM, Dickinson HA, Kitchen BA. Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats. Eur J Pharmacol. 2001 ; 422: 87-90
26. Gordon JA, Hen R. The serotonergic system and anxiety. Neuromolecular Med. 2004 ; 5: 27-40
27. Grillner P, Svensson TH. Nicotine-induced excitation of midbrain dopamine neurons in vitro involves ionotropic glutamate receptoractivation. Synapse. 2000 ; 38: 1-9
28. Jackson A, Nesic J, Groombridge C, Clowry O, Rusted J, Duka T. Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking. Neuropsychopharmacology. 2009 ; 34: 257-265
29. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004 ; 9: 984-997
30. Kenny PJ, Chartoff E, Roberto M, Carlezon WA, Markou A. NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: Role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology. 2009 ; 34: 266-281
31. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl). 2005 ; 179: 4-29
32. Lambe EK, Picciotto MR, Aghajanian GK. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology. 2003 ; 28: 216-225
33. Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron. 2000 ; 27: 349-357
34. Mathew SJ, Price RB, Charney DS. Recent advances in the neurobiology of anxiety disorders: Implications for novel therapeutics. Am J Med Genet C Semin Med Genet. 2008 ; 148C: 89-98
35. Menard J, Treit D. Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci Biobehav Rev. 1999 ; 23: 591-613
36. Moult PR. Neuronal glutamate and GABAA receptor function in health and disease. Biochem Soc Trans. 2009 ; 37: 1317-1322
37. Nakamura M, Jang IS. Presynaptic nicotinic acetylcholine receptors enhance GABAergic synaptic transmission in rat periaqueductal gray neuron. Eur J Pharmacol. 2010 ; 640: 178-184
38. Niewoehner B, Single FN, Hvalby O, Jensen V, Meyer zum Alten, Borgloh S, Seeburg PH, et al. Impaired spatial working memory but spared spatial reference memory following functional loss of NMDA receptors in the dentate gyrus. Eur J Neurosci. 2007 ; 25: 837-846
39. Ouagazzal AM, Kenny PJ, File SE. Modulation of behaviour on trials 1 and 2 in the elevated plus-maze test of anxiety after systemic and hippocampal administration of nicotine. Psychopharmacology (Berl). 1999 ; 144: 54-60
40. Padovan CM, Del Bel EA, Guimaraes FS. Behavioral effects in the elevated plus maze of an NMDA antagonist injected into the dorsal hippocampus: Influence of restraint stress. Pharmacol Biochem Behav. 2000 ; 67: 325-330
41. Paxinos G, Watson C The Rat Brain in Stereotaxic Coordinates. 2007 ) The Rat Brain in Stereotaxic Coordinates, 6th edn. Amsterdam: Academic Press. Amsterdam: Academic Press ; 2007 :
42. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985 ; 14: 149-167
43. Pitkanen A, Jolkkonen E, Kemppainen S. Anatomic heterogeneity of the rat amygdaloid complex. Folia Morphol (Warsz). 2000 ; 59: 1-23
44. Porter JH, Wiley JL, Balster RL. Effects of phencyclidine-like drugs on punished behavior in rats. J Pharmacol Exp Ther. 1989 ; 248: 997-1002
45. Radcliffe KA, Fisher JL, Gray R, Dani JA. Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Ann NY Acad Sci. 1999 ; 868: 591-610
46. Randall-Thompson JF, Pescatore KA, Unterwald EM. A role for delta opioid receptors in the central nucleus of the amygdala in anxiety-like behaviors. Psychopharmacology. 2010 ; 212: 585-595
47. Rezayof A, Hosseini SS, Zarrindast MR. Effects of morphine on rat behaviour in the elevated plus maze: The role of central amygdala dopamine receptors. Behav Brain Res. 2009 ; 202: 171-178
48. Rezayof A, Shirazi-Zand Z, Zarrindast MR, Nayer-Nouri T. Nicotine improves ethanol-induced memory impairment: The role of dorsal hippocampal NMDA receptors. Life Sci. 2010 ; 86: 260-266
49. Rezvanfard M, Zarrindast MR, Bina P. Role of ventral hippocampal GABA(A) and NMDA receptors in the anxiolytic effect of carbamazepine in rats using the elevated plus maze test. Pharmacology. 2009 ; 84: 356-366
50. Rezvani AH, Levin ED. Nicotinic-glutamatergic interactions and attentional performance on an operant visual signal detection task in female rats. Eur J Pharmacol. 2003 ; 465: 83-90
51. Rodgers RJ, Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev. 1997 ; 21: 801-810
52. Rodgers RJ, Johnson NJ. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav. 1995 ; 52: 297-303
53. Rosen JB, Donley MP. Animal studies of amygdala function in fear and uncertainty: Relevance to human research. Biol Psychol. 2006 ; 73: 49-60
54. Sah P, Faber ES, Lopez De Armentia M, Power J. The amygdaloid complex: Anatomy and physiology. Physiol Rev. 2003 ; 83: 803-834
55. Shiffman S. Assessing smoking patterns and motives. J Consult Clin Psychol. 1993 ; 61: 732-742
56. Strauss CV, Maisonnette SS, Coimbra NC, Zangrossi H. Effects of N-methyl-D-aspartate-induced amygdala lesion in rats submitted to the elevated T-maze test of anxiety. Physiol Behav. 2003 ; 78: 157-163
57. Sullivan MA, Covey LS. Nicotine dependence: The role for antidepressants and anxiolytics. Curr Opin Investig Drugs. 2002 ; 3: 262-271
58. Szyndler J, Sienkiewicz-Jarosz H, Maciejak P, Siemiatkowski M, Rokicki D, Czlonkowska AI, Plaznik A. The anxiolytic-like effect of nicotine undergoes rapid tolerance in a model of contextual fear conditioning in rats. Pharmacol Biochem Behav. 2001 ; 69: 511-518
59. Toth E, Sershen H, Hashim A, Vizi ES, Lajtha A. Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: Role of glutamic acid. Neurochem Res. 1992 ; 17: 265-271
60. Uchiyama H, Toda A, Hiranita T, Watanabe S, Eyanagi R. Role of amygdaloid nuclei in the anxiolytic-like effect of nociceptin/orphanin FQ in rats. Neurosci Lett. 2008 ; 431: 66-70
61. Wang C, Marx CE, Morrow AL, Wilson WA, Moore SD. Neurosteroid modulation of GABAergic neurotransmission in the central amygdala: A role for NMDA receptors. Neurosci Lett. 2007 ; 415: 118-123
62. Watanabe T, Nakagawa T, Yamamoto R, Maeda A, Minami M, Satoh M. Involvement of glutamate receptors within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Jpn J Pharmacol. 2002 ; 88: 399-406
63. Wiley JL, Cristello AF, Balster RL. Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Eur J Pharmacol. 1995 ; 294: 101-107
64. Wright MJ, Vann RE, Gamage TF, Damaj MI, Wiley JL. Comparative effects of dextromethorphan and dextrorphan on nicotine discrimination in rats. Pharmacol Biochem Behav. 2006 ; 85: 507-513
65. Yamada H, Bruijnzeel AW. Stimulation of α2-adrenergic receptors in the central nucleus of the amygdala attenuates stress-induced reinstatement of nicotine seeking in rat. Neuropharmacology. 2010 ; 60: 303-311
66. Zakharova ES, Danysz W, Bespalov AY. Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats. Psychopharmacology (Berl). 2005 ; 179: 128-135
67. Zarrindast MR, Homayoun H, Babaie A, Etminani A, Gharib B. Involvement of adrenergic and cholinergic systems in nicotine-induced anxiogenesis in mice. Eur J Pharmacol. 2000 ; 407: 145-158
68. Zarrindast MR, Moghadam AH, Rostami P, Roohbakhsh A. The effects of histaminergic agents in the central amygdala of rats in the elevated plus-maze test of anxiety. Behav Pharmacol. 2005 ; 16: 643-649
69. Zarrindast MR, Naghdi-Sedeh N, Nasehi M, Sahraei H, Bahrami F, Asadi F. The effects of dopaminergic drugs in the ventral hippocampus of rats in the nicotine-induced anxiogenic-like response. Neurosci Lett. 2010 ; 475: 156-160
70. Zarrindast MR, Sarahroodi S, Arzi A, Khodayar MJ, Taheri-Shalmani S, Rezayof A. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: Interaction with the opioid system. Behav Pharmacol. 2008a ; 19: 716-723
71. Zarrindast MR, Sarahroodi S, Arzi A, Khodayar MJ, Taheri-Shalmani S, Rezayof A. Cannabinoid CB1 receptorsofthe rat central amygdala mediate anxiety-like behaviour:Interaction with the opioid system. Behav Pharmacol. 2008b ; 19: 716-723